BCM
CDLX icon

Bayesian Capital Management’s Cardlytics CDLX Stock Holding History

Bayesian Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,081
Closed -$680K – 790
2019
Q4 		$680K Buy
+1,081
New +$529K 0.12% 235

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bayesian Capital Management's CDLX Position: Q1 2020 in Review

Bayesian Capital Management sold out of Cardlytics (CDLX) in Q1 2020, closing a stake of 1,081 shares — an estimated $680K sold.

Bayesian Capital Management first reported a position in CDLX in Q4 2019 and held it in 1 quarter. The position peaked at $680K in Q4 2019. 142 funds tracked by Wall St. Rank hold CDLX as of Q1 2020.

  • Bayesian Capital Management reported no remaining Cardlytics position as of Q1 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 1,081 Cardlytics shares in Q1 2020, an estimated $680K.
  • Bayesian Capital Management first reported a position in Cardlytics in Q4 2019 and held it in 1 quarter.
  • Bayesian Capital Management's Cardlytics position peaked at $680K in Q4 2019.
  • 142 funds tracked by Wall St. Rank held Cardlytics as of Q1 2020.

Based on Bayesian Capital Management's 13F filing for Q1 2020, filed 15 May 2020.